Federated Hermes Inc. Lowers Stock Position in 4D Molecular Therapeutics, Inc. $FDMT

Federated Hermes Inc. decreased its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 4.3% in the 3rd quarter, Holdings Channel reports. The firm owned 1,594,832 shares of the company’s stock after selling 72,506 shares during the period. Federated Hermes Inc.’s holdings in 4D Molecular Therapeutics were worth $13,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at about $46,000. Millennium Management LLC grew its holdings in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after buying an additional 213,264 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the 1st quarter valued at about $39,000. Privium Fund Management B.V. raised its stake in 4D Molecular Therapeutics by 50.7% during the 2nd quarter. Privium Fund Management B.V. now owns 197,458 shares of the company’s stock valued at $733,000 after acquiring an additional 66,458 shares during the last quarter. Finally, Peapod Lane Capital LLC raised its stake in 4D Molecular Therapeutics by 62.6% during the 2nd quarter. Peapod Lane Capital LLC now owns 318,537 shares of the company’s stock valued at $1,182,000 after acquiring an additional 122,684 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on FDMT shares. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Finally, Chardan Capital reissued a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, December 18th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $33.25.

4D Molecular Therapeutics Trading Down 1.2%

FDMT stock opened at $8.86 on Friday. The company’s 50-day moving average price is $8.97 and its 200 day moving average price is $8.31. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.23 and a 52 week high of $12.34. The company has a market cap of $506.17 million, a P/E ratio of -2.36 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. On average, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.